STOCK TITAN
  1. Home
  2. Sec-filings
  3. WOK
  4. [6-K] WORK Medical Technology Group LTD Current Report (Foreign Issuer)

WORK Medical (WOK) creates U.S. subsidiary and deepens global biopharma ties

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

WORK Medical Technology Group LTD reported two strategic initiatives. The company formed a wholly owned U.S. subsidiary, Work Bio Technologies Ltd in Nevada, which is intended to become its primary operational platform in the United States, improving supply-chain management and direct business development with U.S. partners.

The company also participated as a partner and exhibitor at the 2026 CBA-China Annual Conference in Wuxi, engaging global biopharmaceutical experts on supply chain collaboration and AI in life sciences. WORK Medical highlighted its move into the “AI+Digital Healthcare” space as part of its long-term international growth strategy.

Positive

  • None.

Negative

  • None.
Form type Form 6-K Report of foreign private issuer for June 2026
Conference dates May 8-10, 2026 2026 CBA-China Annual Conference in Wuxi, China
Product portfolio size 23 products Class I and II medical devices and disposables
China coverage 34 regions Products sold in 34 provincial-level regions in China
International reach 15 products in 30+ countries Products sold outside China
FDA-registered products 17 products Registered with the U.S. Food and Drug Administration
Subsidiary incorporation date April 22, 2026 Work Bio Technologies Ltd formed in Nevada
Subsidiary identifiers Entity ID E56873592026-7; EIN 42-2095406 Work Bio Technologies Ltd corporate details
wholly owned subsidiary financial
"established a wholly-owned subsidiary, Work Bio Technologies Ltd"
A wholly owned subsidiary is a company whose entire ownership is held by another company (the parent), so the parent controls decisions, operations, and finances. Think of it as a fully controlled branch that runs as its own legal entity but whose results flow straight into the parent’s financial statements; investors watch these structures because they affect consolidated revenue, risk exposure, and how profits, liabilities, and cash flow are allocated across the corporate group.
AI+Digital Healthcare technical
"its strategic positioning as a participant in the “AI+Digital Healthcare” sector"
AI+digital healthcare combines artificial intelligence tools (like machine learning algorithms) with digital platforms (such as apps, wearable sensors, and telemedicine) to collect, analyze, and act on health data. Investors care because it can make healthcare faster, cheaper, and more personalized—like adding a smart assistant to routine care—potentially boosting efficiency, opening new services and revenue streams, and changing competitive dynamics in medical markets.
forward-looking statements regulatory
"This press release contains forward-looking statements, including statements made"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995"
Class I and II medical devices medical
"develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of June 2026

 

Commission File Number: 001-42256

 

WORK Medical Technology Group LTD

 

1/88 Cook St, Auckland City, 1001, New Zealand

+1 949-818-3667

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

 

On April 22, 2026, WORK Medical Technology Group LTD, an exempted company incorporated in the Cayman Islands (the “Company”), established a wholly-owned subsidiary, Work Bio Technologies Ltd (“WBT” or the “Subsidiary”), a domestic corporation incorporated in the State of Nevada. WBT is intended to serve as the Company’s primary operational platform in the United States. The Subsidiary is expected to strengthen the Company’s commercial presence by enhancing the Company’s ability to manage supply chains, and develop business relationships directly in the U.S.

 

On June 3, 2026, the Company issued a press release announcing the establishment of WBT to advance global expansion and reinforce long-term growth strategy. A copy of the press releases is attached hereto as Exhibit 99.1.

 

On June 5, 2026, the Company issued a press release announcing the participation as a partner and exhibitor at the 2026 Chinese Biopharmaceutical Association China Branch Annual Conference to deepen engagement with the global biopharmaceutical community. A copy of the press releases is attached hereto as Exhibit 99.2.

 

This report shall be deemed to be incorporated by reference into the registration statement of the Company on Form F-3 (File No. 333-289943) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  WORK Medical Technology Group LTD
     
Date: June 5, 2026 By: /s/ Shuang Wu
  Name:  Shuang Wu
  Title: Chief Executive Officer

 

2

 

EXHIBIT INDEX

 

Exhibit No.   Description
     
99.1   Press Release – WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy
     
99.2   Press Release - WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference

  

3

 

Exhibit 99.1

 

WORK Medical Technology Group Establishes U.S. Subsidiary to Advance Global Expansion and Reinforce Long-Term Growth Strategy

 

Hangzhou, China, June 3, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China today announced the establishment of its U.S. subsidiary, Work Bio Technologies Ltd (“WBT” or the “Subsidiary”), marking a strategic milestone in the Company’s global expansion initiative and long-term growth strategy.

 

In alignment with WORK Medical’s long-term strategy to strengthen its global commercial operations and market development efforts, WBT will serve as the Company’s primary operational platform in the United States. The Subsidiary is expected to strengthen WORK Medical’s commercial presence by enhancing the Company’s ability to manage supply chains, and develop business relationships directly in the U.S.

 

Leveraging its U.S. presence, WBT is also expected to support WORK Medical’s broader international expansion efforts by establishing an operational framework that integrates product distribution, supply chain management, and customer engagement across key global markets. This integrated platform is expected to facilitate business localization, enhance regulatory compliance capabilities, and provide more responsive support to international customers and business partners.

 

Recently incorporated in the State of Nevada (Entity ID: E56873592026-7; EIN: 42-2095406), WBT is a wholly owned subsidiary of WORK Medical Technology Group LTD. Mr. Wu Shuang, Chief Executive Officer and Chairman of WORK Medical, concurrently serves as President, Secretary, Treasurer, and Director of WBT.

 

Mr. Wu Shuang commented, “The establishment of WBT in the United States marks a significant milestone in our vision of becoming a globally connected life sciences and medical technology company. This initiative reflects our confidence in the Company’s long-term strategy and our commitment to serving customers and partners worldwide. By combining a direct U.S. operational presence with our existing capabilities, we believe we are well positioned to accelerate business development, deepen international partnerships, and further strengthen investor confidence in WORK Medical’s global growth strategy.”

 

About WORK Medical Technology Group LTD

 

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 23 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.

 

Forward-Looking Statements

 

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

 

For more information, please contact:

 

WORK Medical Technology Group LTD

Investor Relations Department

Email: ir@workmedtech.com

 

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: investors@ascent-ir.com

Exhibit 99.2

 

WORK Medical Technology Group Participated in 2026 CBA-China Annual Conference

Deepening Engagement with the Global Biopharmaceutical Community

 

Auckland, New Zealand, June 5, 2026 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical”, the “Company” or “we”), a supplier of medical devices in China,,today announced its participation as a partner and exhibitor at the 2026 CBA-China Annual Conference (the “Conference”), held on May 8 to 10, 2026 in Wuxi, Jiangsu Province, China. The Conference was organized by the Chinese Biopharmaceutical Association China Branch (CBA-China) and co-hosted by BioValley, bringing together hundreds of scientists, entrepreneurs, and industry leaders from across the global biopharmaceutical sector.

 

As a partner of the Conference, WORK Medical engaged with senior experts from North America, Europe, and the Asia-Pacific region throughout the three-day event. Discussions focused on global supply chain collaboration, the application of artificial intelligence (“AI”) technologies in life sciences, and opportunities for cooperation involving multimodal AI models in clinical research and translation.

 

The Company’s participation extended beyond showcasing its medical hardware and consumables business. WORK Medical also highlighted its strategic positioning as a participant in the “AI+Digital Healthcare” sector, demonstrating its evolving focus on AI-driven data enablement and digital asset operations. The Company intends to leverage this engagement to establish high-value strategic partnerships with global industry professionals in areas including joint technology development and digital asset management.

 

WORK Medical’s participation in the Conference reflects the Company’s broader strategy of expanding its presence within international professional networks and strengthening its global industry relationships. The Company views active engagement with the global biopharmaceutical community as an important component of its international growth strategy, providing insight into emerging clinical needs and facilitating the development of cross-border partnerships that may support its future innovation initiatives.

 

Management Commentary

 

Mr. Wu Shuang, Chief Executive Officer and Chairman of WORK Medical, commented: “The CBA-China Annual Conference serves as an important platform connecting China’s biopharmaceutical sector with the global scientific community. As a Nasdaq-listed company, WORK Medical views continued engagement with leading international medical professionals as an important element of our globalization strategy. Through participation in this event, we aim to strengthen our presence within the international professional community, deepen our relationships with industry leaders and gain valuable insight into evolving global healthcare trends. We believe these interactions will support our efforts to identify future collaboration opportunities and advance our long-term growth strategy.”

 

About WORK Medical Technology Group LTD

 

WORK Medical Technology Group LTD, through its subsidiary, Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and its subsidiaries in China, is a supplier of medical devices that develops and manufactures Class I and II medical devices and sells Class I and II disposable medical devices through operating subsidiaries in China. The Company has a diverse product portfolio comprising 23 products, including customized and multifunctional masks and other medical consumables. All the products have been sold in 34 provincial-level administrative regions in China, with 15 of them sold in more than 30 countries worldwide. The Company has received a number of quality-related manufacturing designations and has registered 17 products with the U.S. Food and Drug Administration allowing their products to enter the U.S. market. For more information, please visit the Company’s website: https://www.workmedtech.com/corporate.

 

Forward-Looking Statements

 

This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and variations of these words or similar expressions that are intended to identify forward-looking statements. Any such statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Any forward-looking statements in this press release are based on the Company’s current expectations, estimates and projections only as of the date of this release and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results set forth in the Company’s annual report on Form 20-F and other documents filed by the Company with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

 

For more information, please contact:

 

WORK Medical Technology Group LTD

Investor Relations Department

Email: ir@workmedtech.com

 

Ascent Investor Relations LLC

Tina Xiao

Phone: +1-646-932-7242

Email: investors@ascent-ir.com

 

Source: View Original Filing on SEC EDGAR

FAQ

What did WORK Medical Technology Group LTD (WOK) announce in this Form 6-K?

WORK Medical reported creating a U.S. subsidiary and joining a major biopharma conference. The new Nevada-based unit will serve as its primary U.S. operational platform, while conference participation supports relationship-building and aligns with the company’s global expansion and AI-focused digital healthcare strategy.

How does the new U.S. subsidiary support WORK Medical’s (WOK) global strategy?

The U.S. subsidiary is expected to strengthen global expansion by integrating distribution, supply chain, and customer engagement. Management sees it helping business localization, regulatory compliance, and more responsive support for international customers, aligning with the company’s long-term growth strategy.

What was WORK Medical’s role at the 2026 CBA-China Annual Conference?

WORK Medical participated as a partner and exhibitor at the 2026 CBA-China Annual Conference. The company engaged scientists and industry leaders on global supply chains, AI applications in life sciences, and multimodal AI models, aiming to build strategic partnerships and support its international growth initiatives.

How is WORK Medical (WOK) positioning itself in AI and digital healthcare?

The company presented itself as an “AI+Digital Healthcare” participant, emphasizing AI-driven data enablement and digital asset operations. It plans to leverage conference engagement and its new U.S. presence to pursue joint technology development and digital asset management partnerships with global biopharmaceutical professionals.

What products and regulatory footprint does WORK Medical currently have?

WORK Medical develops and manufactures Class I and II medical devices and sells related disposables. Its portfolio includes 23 products sold across 34 regions in China, with 15 products marketed in over 30 countries and 17 products registered with the U.S. Food and Drug Administration.

Filing Exhibits & Attachments

2 documents

Press Releases